E2F3 and ovarian carcinoma: In ovarian cancer, it was found that E2F1/2/5/8 are poor prognostic biomarkers and therapeutic targets [35]]; in contrast, Yao et al. demonstrated that E2F1/2/3/5/7/8 are potential biomarkers for the diagnosis of colon cancer and E2F3/4/7/8 are potential targets of precision therapy [28].